NU7441 (KU-57788)

Name: NU7441 (KU-57788)
Brand: Selleck Chemicals
SKU: S2638
Rating: 5 (143 reviews)

For research use only.

Catalog No.S2638

143 publications

CAS No. 503468-95-9

NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits mTOR and PI3K with IC50 of 1.7 μM and 5 μM in cell-free assays, respectively. It reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage.

Selleck's NU7441 (KU-57788) has been cited by 143 publications

Nature, 2020, 10.1038/s41586-020-2960-y

PubMed: 33239783 ( click the link to review the publication )

Nature, 2019, 74(7779):571-574

PubMed: 31645724 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):396-410

PubMed: 30205044 ( click the link to review the publication )

Nat Biotechnol, 2017, 35(5):463-474

PubMed: 28319085 ( click the link to review the publication )

Blood, 2020, 5 pii: blood

PubMed: 32369572 ( click the link to review the publication )

Adv Sci (Weinh), 2020, 7(20):2000157

PubMed: 33101843 ( click the link to review the publication )

Mol Cell, 2020, S1097-2765(20)30723-1

PubMed: 33152268 ( click the link to review the publication )

Nat Commun, 2020, 11(1):6182

PubMed: 33273464 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5775

PubMed: 33188175 ( click the link to review the publication )

Nucleic Acids Res, 2020, 10.1093/nar/gkaa022

PubMed: 31965183 ( click the link to review the publication )

Nucleic Acids Res, 2020, gkaa782

PubMed: 33010172 ( click the link to review the publication )

Sci Immunol, 2020, 5(43)

PubMed: 31980485 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-20-2269

PubMed: 32967938 ( click the link to review the publication )

J Cell Biol, 2020, 219(11)e202001063

PubMed: 33007086 ( click the link to review the publication )

Cell Rep, 2020, 32(8):108068

PubMed: 32846126 ( click the link to review the publication )

Cell Rep, 2020, 32(11):108140

PubMed: 32937135 ( click the link to review the publication )

Cell Rep, 2020, 33(2):108240

PubMed: 33053351 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 4;5(1):20

PubMed: 32296021 ( click the link to review the publication )

Mol Oncol, 2020, 26

PubMed: 32336009 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0507

PubMed: 32229503 ( click the link to review the publication )

Front Oncol, 2020, 10:575711

PubMed: 33178606 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(17)E6383

PubMed: 32887472 ( click the link to review the publication )
Int J Oncol, 2020, 57(4):939-955

PubMed: 32945394 ( click the link to review the publication )

Int J Radiat Biol, 2020, 1-7

PubMed: 33074046 ( click the link to review the publication )

J Cell Physiol, 2020, 10.1002/jcp.29927

PubMed: 32686190 ( click the link to review the publication )

Nucleic Acids Res, 2020, 48(2):736-747

PubMed: 31740976 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9):E2356

PubMed: 32825402 ( click the link to review the publication )

Cancers (Basel), 2020, 12(6):1490

PubMed: 32517381 ( click the link to review the publication )

Oncotarget, 2020, 11(7):699-726

PubMed: 32133046 ( click the link to review the publication )

NAR Cancer, 2020, 2(2):zcaa006

PubMed: 32743550 ( click the link to review the publication )

Elife, 2020, 9:e57894

PubMed: 32628111 ( click the link to review the publication )

J Biol Chem, 2020, 295(1):125-137

PubMed: 31753920 ( click the link to review the publication )

Int J Mol Med, 2020, 45(6):1673-1684

PubMed: 32186748 ( click the link to review the publication )

Cell Rep, 2020, 32(6):108018

PubMed: 32783940 ( click the link to review the publication )

Toxicol Lett, 2020, 318:104-113

PubMed: 31672611 ( click the link to review the publication )

Biomed Pharmacother, 2020, 129:110427

PubMed: 32574974 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5304

PubMed: 31757956 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1577

PubMed: 30952868 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3925

PubMed: 31477700 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2866

PubMed: 31253785 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(18):5608-5622

PubMed: 31266829 ( click the link to review the publication )

Genes Dev, 2019, 33(17-18):1175-1190

PubMed: 31395742 ( click the link to review the publication )

Haematologica, 2019, 104(11):2225-2240

PubMed: 30819918 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32558

PubMed: 31283004 ( click the link to review the publication )

Oncogene, 2019, 38(14):2451-2463

PubMed: 30532030 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31480356 ( click the link to review the publication )
Br J Cancer, 2019, 121(7):600-610

PubMed: 31481733 ( click the link to review the publication )

FASEB J, 2019, 33(1):1138-1150

PubMed: 30106602 ( click the link to review the publication )

FASEB J, 2019, 33(11):11668-11681

PubMed: 31348687 ( click the link to review the publication )

FASEB J, 2019, 33(6):6778-6788

PubMed: 30807703 ( click the link to review the publication )

PLoS Genet, 2019, 15(2):e1007925

PubMed: 30716077 ( click the link to review the publication )

J Environ Manage, 2019, 244:77-82

PubMed: 31108313 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(12):2457-2468

PubMed: 31551253 ( click the link to review the publication )

Toxicol Sci, 2019, 10.1093/toxsci/kfz178

PubMed: 31388677 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(24)E6316

PubMed: 31847370 ( click the link to review the publication )

J Biol Chem, 2019, 294(8):2827-2838

PubMed: 30598506 ( click the link to review the publication )

Mol Cell Biol, 2019, 39(24)e00181-19

PubMed: 31591143 ( click the link to review the publication )

J Pharmacol Exp Ther, 2019, 371(2):320-326

PubMed: 31455631 ( click the link to review the publication )

Retrovirology, 2019, 16(1):13

PubMed: 31036006 ( click the link to review the publication )

Front Physiol, 2019, 10:616

PubMed: 31178753 ( click the link to review the publication )

BMC Pulm Med, 2019, 19(1-:165

PubMed: 31464599 ( click the link to review the publication )

Mol Biol Rep, 2019, 10.1007/s11033-019-04605-0

PubMed: 31020489 ( click the link to review the publication )

Mol Biol Rep, 2019, 10.1007/s11033-019-05105-x

PubMed: 31583565 ( click the link to review the publication )

Mol Med Rep, 2019, 20(4):3609-3616

PubMed: 31485633 ( click the link to review the publication )

FEBS Open Bio, 2019, 9(7):1315-1326

PubMed: 31141305 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(21):10977-10993

PubMed: 31612207 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(18):9467-9479

PubMed: 31396623 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(16):8838-8859

PubMed: 31329944 ( click the link to review the publication )

Cell Res, 2018, 28(7):756-770

PubMed: 29844578 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5351

PubMed: 30559436 ( click the link to review the publication )
Cell Rep, 2018, 24(4):987-1000

PubMed: 30044993 ( click the link to review the publication )

Int J Cancer, 2018,

PubMed: 29363109 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):931

PubMed: 30209297 ( click the link to review the publication )

FASEB J, 2018, 32(4):1818-1829

PubMed: 29162700 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Hum Mol Genet, 2018, 27(23):4024-4035

PubMed: 30107443 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):428-438

PubMed: 29222170 ( click the link to review the publication )

DNA Repair (Amst), 2018, 68:68-74

PubMed: 30017059 ( click the link to review the publication )

Mol Biol Cell, 2018, 29(15):1786-1797

PubMed: 29897835 ( click the link to review the publication )

Int J Mol Sci, 2018,

PubMed: 30115874 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9685

PubMed: 29946146 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(10):5050-5060

PubMed: 29660033 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(17):8926-8939

PubMed: 30113698 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14421

PubMed: 30258062 ( click the link to review the publication )

Biochem Biophys Rep, 2018, 16:115-121

PubMed: 30417129 ( click the link to review the publication )

Oncotarget, 2018, 9(9):8560-8572

PubMed: 29492217 ( click the link to review the publication )

JCI Insight, 2018, 3(3)98096

PubMed: 29415883 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(1):244-254

PubMed: 28069995 ( click the link to review the publication )

Cancer Immunol Res, 2017, 5(9):790-803

PubMed: 28775208 ( click the link to review the publication )

Cancer Res, 2017, 77(17):4567-4578

PubMed: 28698210 ( click the link to review the publication )

Cancer Res, 2017, 77(18):4745-4754

PubMed: 28754673 ( click the link to review the publication )

J Cell Biol, 2017, 216(3):623-639

PubMed: 28228534 ( click the link to review the publication )

EMBO Rep, 2017, 18(8):1412-1428

PubMed: 28615293 ( click the link to review the publication )

J Biol Chem, 2017, 292(30):12424-12435

PubMed: 28592488 ( click the link to review the publication )
Mol Biol Cell, 2017, 28(26):3756-3772

PubMed: 29074567 ( click the link to review the publication )

Int J Biochem Cell Biol, 2017, 92:164-172

PubMed: 28827033 ( click the link to review the publication )

Radiat Res, 2017, 188(6):597-604

PubMed: 28952912 ( click the link to review the publication )

PLoS One, 2017, 12(7):e0181608

PubMed: 28750002 ( click the link to review the publication )

DNA Repair (Amst), 2017, 54:30-39

PubMed: 28448822 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90037-90049

PubMed: 29163809 ( click the link to review the publication )

Oncotarget, 2017, 8(2):2916-2935

PubMed: 27935866 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(11):1196-1207

PubMed: 27723717 ( click the link to review the publication )

blood, 2016, 10.1182/blood-2016-02-700328

PubMed: ( click the link to review the publication )

Blood, 2016, 128(4):574-83

PubMed: 27235137 ( click the link to review the publication )

Nat Commun, 2016, 7:12880

PubMed: 27634057 ( click the link to review the publication )

Oncogene, 2016, 35(5):577-586

PubMed: 25893305 ( click the link to review the publication )

Cancer Lett, 2016, 383(1):41-52

PubMed: 27693461 ( click the link to review the publication )

Cell Death Dis, 2016, 7(7):e2316

PubMed: 27468692 ( click the link to review the publication )

Cell Cycle, 2016, 15(1):84-94

PubMed: 26771713 ( click the link to review the publication )

PLoS One, 2016, 11(12):e0167454

PubMed: 27907109 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

PLoS One, 2016, 11(9):e0163049

PubMed: 27643854 ( click the link to review the publication )

Nucleic Acids Res, 2016, 44(11):5204-17

PubMed: 27001513 ( click the link to review the publication )

Oncotarget, 2016, 7(38):60807-60822

PubMed: 27602502 ( click the link to review the publication )

Nucleic Acids Res, 2016, 44(8):3695-712

PubMed: 26843428 ( click the link to review the publication )

Oncotarget, 2016, 7(40):65504-65513

PubMed: 27602767 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(9):1158-68

PubMed: 26237645 ( click the link to review the publication )

Leukemia, 2015, 29(5):1133-42

PubMed: 25371178 ( click the link to review the publication )
Genome Med, 2015, 10.1186/s13073-015-0215-6

PubMed: 26307031 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(8):1896-906

PubMed: 26026052 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: 25232030 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(11):1585-92

PubMed: 26382920 ( click the link to review the publication )

Cell Cycle, 2015, 14(23):3713-24

PubMed: 26505547 ( click the link to review the publication )

PLoS ONE, 2015,

PubMed: 26065416 ( click the link to review the publication )

Anticancer Res, 2015, 35(7):3829-38

PubMed: 26124328 ( click the link to review the publication )

Oncotarget, 2015, 6(16):14005-25

PubMed: 26087309 ( click the link to review the publication )

Nucleic Acids Res, 2014, 42(12):7776-92

PubMed: 24906880 ( click the link to review the publication )

Nucleic Acids Res, 2014, 42(9):5616-32

PubMed: 24598253 ( click the link to review the publication )

Genes Dev, 2014, 28(8):875-87

PubMed: 24700029 ( click the link to review the publication )

Cancer Res, 2014, 74(16):4282-94

PubMed: 24894717 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.268

PubMed: 25132265 ( click the link to review the publication )

ACS Chem Biol, 2014, 9(5):1160-71

PubMed: 24568369 ( click the link to review the publication )

Toxicol Sci, 2014, 10.1093/toxsci/kfu207

PubMed: 25288669 ( click the link to review the publication )

Biosci Rep, 2014, 34(3)

PubMed: 24844881 ( click the link to review the publication )

Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 2014,

PubMed: ( click the link to review the publication )

Uppsala University, 2014, Department of Radiology

PubMed: ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(22):10157-69

PubMed: 24021630 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(7):4080-92

PubMed: 23449221 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(15):7378-86

PubMed: 23775790 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2013, 88(2):385-94

PubMed: 24411611 ( click the link to review the publication )

Purity & Quality Control

Choose Selective DNA-PK Inhibitors

Biological Activity

Description

Targets

DNA-PK ^[1] (Cell-free assay)	mTOR ^[1] (cell-free assay)	PI3K ^[1] (cell-free assay)
14 nM	1.7 μM	5 μM

In vitro

NU7441 increases the persistence of γH2AX foci after ionizing radiation–induced or etoposide-induced DNA damage. NU7441 (0.5 μM or 1 μM) appreciably increases G2-M accumulation induced by ionizing radiation, etoposide, and doxorubicin in both SW620 and LoVo cells. ^[2] NU7441 causes persistence of doxorubicin- and ionising radiation-induced DNA double-strand break and also slightly decreases homologous recombination activity DNA-PK-proficient M059-Fus-1 and DNA-PK-deficient M059 J human tumour cells. ^[3] NU7441 inhibits UV-induced RPA p34 hyperphosphorylation in a dose-dependent manner both in cells lacking and cells expressing polymerase η. ^[4] NU7441 increases levels of fludarabine-induced γH2AX foci and correspondingly decreased fludarabine-induced cell death in chronic lymphocytic leukemia cells. ^[5] NU7441 also inhibits mitoxantrone-induced DNA-PKcs autophosphorylation and repair in chronic lymphocytic leukemia cells. ^[6] It reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage^[7].

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
NCI-H1770	M2T5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTBwMEKxOFMh\|ryP	NF\RdpRUSU6JRWK=
A172	NVi4dYNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTBwMUWzNVYh\|ryP	M3;ye3NCVkeHUh?=
NCI-H526	NWHjXGc2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPwTWM2OD1yLkK4OFA4KM7:TR?=	M1;CPHNCVkeHUh?=
HDLM-2	NUTH[FJrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTBwM{KzOFUh\|ryP	M2rsbHNCVkeHUh?=
HuO-3N1	M3;3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;YW2lEPTB;MD60OlY{PiEQvF2=	M{LjXXNCVkeHUh?=
NCI-SNU-1	M{\DXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTBwNkC5PVQh\|ryP	NGnvR4xUSU6JRWK=
SK-N-AS	MnvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTBwNkKyNVYh\|ryP	NXnGZ3p7W0GQR1XS
LoVo	MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvTSWJKSzVyPUCuPFY4PDlizszN	M4PRTHNCVkeHUh?=
LAMA-84	M1nTS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTBwOUi4N\|Mh\|ryP	NV[2XFhCW0GQR1XS
CTB-1	NVTsOVc2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHf3bm1KSzVyPUGuNVE2PDZizszN	NE\IdotUSU6JRWK=
KP-N-YS	NVz0W2RZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37JVGlEPTB;MT6xOFI{OSEQvF2=	MlL5V2FPT0WU
HH	MnLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\GR2pNUUN3ME2xMlE5ODl\|IN88US=>	MXzTRW5ITVJ?
CHL-1	Ml7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M12zZmlEPTB;MT6yNVM3QCEQvF2=	NH7zW3lUSU6JRWK=
NB7	NXzqOG9ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnxTWM2OD1zLkK0O\|Q2KM7:TR?=	NWS4W3JSW0GQR1XS
HL-60	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;UZnVRUUN3ME2xMlM5OTlizszN	M13mN3NCVkeHUh?=
639-V	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\RcWdKSzVyPUGuOFQyOjhizszN	NH7sdJNUSU6JRWK=
NCI-H1793	NHW5NZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LERmlEPTB;MT60OVg1KM7:TR?=	Ml3FV2FPT0WU
NEC8	M1nER2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljVTWM2OD1zLkW1N\|Uh\|ryP	NXLKfogyW0GQR1XS
PA-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVmzSZNFUUN3ME2xMlU5Ojl2IN88US=>	MXnTRW5ITVJ?
D-423MG	NGTpUI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHPZUWhKSzVyPUGuOlk{PjFizszN	NVrye5lFW0GQR1XS
NCI-H292	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M17BdGlEPTB;MT63OFAyOyEQvF2=	NV3KR2FCW0GQR1XS
SK-MEL-1	MkXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1rxcmlEPTB;MT63PVQ4QSEQvF2=	MlLZV2FPT0WU
LB2241-RCC	NFSwZW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGSwO5lKSzVyPUKuNVQyPDZizszN	MWnTRW5ITVJ?
SK-MEL-3	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTJwMU[0PUDPxE1?	M3PRfXNCVkeHUh?=
MHH-PREB-1	MljDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnsTWM2OD1{LkG2OlA6KM7:TR?=	MY\TRW5ITVJ?
BFTC-905	MkXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvnSIJwUUN3ME2yMlE3Pjh5IN88US=>	NYHMbZF[W0GQR1XS
Ramos-2G6-4C10	M1fafWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLMbm9KSzVyPUKuNVk6ODlizszN	NVrsO5hYW0GQR1XS
G-361	MmfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37xe2lEPTB;Mj6yNVY5KM7:TR?=	MWjTRW5ITVJ?
MOLT-4	NWTaOFl2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV7JR\|UxRTJwMkG4PFgh\|ryP	NGTyXXJUSU6JRWK=
DEL	M1rBe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{DLOmlEPTB;Mj6zOVU3PCEQvF2=	M1X0cXNCVkeHUh?=
MV-4-11	NHvjW5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHDTWM2OD1{LkO3N\|kh\|ryP	MWTTRW5ITVJ?
SK-NEP-1	NIW1[JRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHESYIzUUN3ME2yMlM5Pzh\|IN88US=>	NXznW\|VNW0GQR1XS
RS4-11	NFjKPG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3ac4RKSzVyPUKuOVYxOjNizszN	M3vhcXNCVkeHUh?=
HuH-7	NF;4[2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDXTWM2OD1{LkW2O\|AzKM7:TR?=	NUT0flQzW0GQR1XS
A101D	NH[2U4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrqbItKSzVyPUKuOlE{OzhizszN	MXzTRW5ITVJ?
KG-1	M4XpPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTJwNke5NlQh\|ryP	NHX5OWhUSU6JRWK=
KALS-1	NEfzSJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLwSlVKSzVyPUKuOlk3OzNizszN	NFPQb\|ZUSU6JRWK=
VMRC-RCZ	NWfWXolCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVzJR\|UxRTJwN{ezNlgh\|ryP	NV6xfnc{W0GQR1XS
SK-UT-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTNwMUWzNUDPxE1?	M{[zdnNCVkeHUh?=
SW962	NVvPU3FNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnKWHd6UUN3ME2zMlIxOzV{IN88US=>	NYTsOY5CW0GQR1XS
DBTRG-05MG	NFnIbI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLpTWM2OD1\|LkK4NFg2KM7:TR?=	NE\5dYlUSU6JRWK=
PANC-08-13	M2LFOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTNT2ZKSzVyPUOuOFEzPzhizszN	NWO0[WZ4W0GQR1XS
QIMR-WIL	M1XWWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXlc3pKSzVyPUOuOFE{PDFizszN	NF\XVoVUSU6JRWK=
SK-MEL-30	NELwb4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1zQV2lEPTB;Mz60NlU6QCEQvF2=	NF;nfGRUSU6JRWK=
697	NF;sTmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTNwNES5PVMh\|ryP	MmXOV2FPT0WU
NY	NFyzSJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTNwNEWwNlIh\|ryP	NVnRRm5PW0GQR1XS
ES7	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXVTWM2OD1\|LkS2O\|I6KM7:TR?=	NFjXVlRUSU6JRWK=
JVM-3	NFrUZppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrL[3JKSzVyPUOuOFgxPzdizszN	MkjJV2FPT0WU
U031	NEDPXpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHkV5g1UUN3ME2zMlU6OzZ6IN88US=>	NYnXbpBjW0GQR1XS
BHT-101	NYn2XIdRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTNwNUm5PFUh\|ryP	Mn31V2FPT0WU
8305C	NIG5TJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTNwNkG3N\|Yh\|ryP	M2HWTHNCVkeHUh?=
MG-63	NUHwUGI4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPWW4NKSzVyPUOuOlI3PzZizszN	MormV2FPT0WU
NOS-1	NEWweZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoX4TWM2OD1\|Lk[1N\|EzKM7:TR?=	MnvCV2FPT0WU
YH-13	M4jlbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTZN5pyUUN3ME2zMlg4OTh7IN88US=>	NVu1UXVOW0GQR1XS
LXF-289	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTNwOUGwOFEh\|ryP	MmLtV2FPT0WU
GOTO	NVfUVZFST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHzdm5rUUN3ME2zMlkyPDlizszN	MXnTRW5ITVJ?
EKVX	MmnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPYeI9mUUN3ME20MlIzPTJ2IN88US=>	M2XtW3NCVkeHUh?=
CAL-51	Mme2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH31Z3FKSzVyPUSuNlQ5PTRizszN	M{OwSHNCVkeHUh?=
AN3-CA	NXrVSWl[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTRwMkW4NVMh\|ryP	MmHsV2FPT0WU
IA-LM	NHji[I9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnJVXFKSzVyPUSuNlc6OzVizszN	MkSzV2FPT0WU
KU-19-19	MkP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PH[WlEPTB;ND6zNlkzOSEQvF2=	M3LSR3NCVkeHUh?=
A704	NHTre\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTRwNEC4PFgh\|ryP	MlPUV2FPT0WU
RH-18	MmeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXX[JJKSzVyPUSuOFQ6PTNizszN	NGDYSoVUSU6JRWK=
IST-MEL1	NHfxb5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\kT2lEPTB;ND61PFI3OyEQvF2=	MU\TRW5ITVJ?
LU-134-A	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFu4RmpKSzVyPUSuOVk3QDVizszN	NXq5[llTW0GQR1XS
SF126	NULFfXdzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPQTWM2OD12Lk[wO\|E2KM7:TR?=	NIqxdXNUSU6JRWK=
EFO-27	Mn\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGeyVlJKSzVyPUSuOlY2OjVizszN	MWnTRW5ITVJ?
SN12C	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTRwN{G4PVgh\|ryP	M3nj[nNCVkeHUh?=
L-363	M{Hid2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTUTWM2OD12Lke3NVE3KM7:TR?=	MUTTRW5ITVJ?
MEL-HO	M4fOdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTRwN{e5PFkh\|ryP	NYTuWJhUW0GQR1XS
TYK-nu	MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlKwTWM2OD12LkiwNVI5KM7:TR?=	NEf0dmhUSU6JRWK=
MDA-MB-415	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIi5[FRKSzVyPUWuNFA{OTRizszN	MUfTRW5ITVJ?
HCC70	NXztR2VXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkW0TWM2OD13LkCzPVM6KM7:TR?=	MYPTRW5ITVJ?
IGROV-1	NFTTWYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfTTWM2OD13LkK1NlkzKM7:TR?=	Mn\BV2FPT0WU
NCI-H1355	MkmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDxfopKSzVyPUWuNlk3KM7:TR?=	M3q0VXNCVkeHUh?=
23132-87	NV3lVGplT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTVwM{KwNlQh\|ryP	M4HKNnNCVkeHUh?=
NB69	M2DvdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTVwM{K0NkDPxE1?	NFv0UHBUSU6JRWK=
HSC-2	NFrkb4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUe3[G1[UUN3ME21MlQyPzd\|IN88US=>	M{nyPHNCVkeHUh?=
KYSE-410	NGLWPFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTVwNEe2N\|Yh\|ryP	M3zoRXNCVkeHUh?=
GCIY	NELWVXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHflcVVKSzVyPUWuOVE{PzhizszN	MlnmV2FPT0WU
A427	M3HJZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTVwNUO2OlEh\|ryP	MWPTRW5ITVJ?
ChaGo-K-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWj5Zod6UUN3ME21MlU3PTl7IN88US=>	NXyxNHdGW0GQR1XS
PFSK-1	M3Sz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnuyTWM2OD13Lk[yNVk1KM7:TR?=	NYDncYpuW0GQR1XS
MLMA	NH3POWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnFTWM2OD13LkizOlA3KM7:TR?=	NYHxeXBbW0GQR1XS
RVH-421	M2\vZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHuTWM2OD14LkC3N\|M5KM7:TR?=	MmrMV2FPT0WU
LB1047-RCC	NUj4Z25JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXpXWZNUUN3ME22MlE4PTJ{IN88US=>	NGrDR21USU6JRWK=
MHH-NB-11	M4jyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzYUZVKSzVyPU[uN\|I4OjFizszN	M2DmU3NCVkeHUh?=
J-RT3-T3-5	NHvxS3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIfO[WtKSzVyPU[uOlMzQTFizszN	MofPV2FPT0WU
UM-UC-3	NEjBeJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTBTWM2OD14Lk[0N\|M1KM7:TR?=	NWqyXJV1W0GQR1XS
IST-SL1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlO1TWM2OD14Lk[5N\|Y6KM7:TR?=	NFSyTYtUSU6JRWK=
NB14	NGr0N5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIK3bpdKSzVyPU[uO\|k4PjFizszN	M4fqVXNCVkeHUh?=
NBsusSR	NEnIeYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIX2R2ZKSzVyPU[uPFI2ODJizszN	NXTYdlVsW0GQR1XS
D-263MG	M2fSVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTZwOUGwOlgh\|ryP	MUDTRW5ITVJ?
NCI-H2347	MkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTZwOUOyNVMh\|ryP	MYDTRW5ITVJ?
ES8	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFjNWZNKSzVyPU[uPVc2QDhizszN	M2O2[nNCVkeHUh?=
786-0	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\ETWM2OD15LkC5O\|g3KM7:TR?=	NFriZnpUSU6JRWK=
EPLC-272H	NEnMTGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnSxTWM2OD15LkG2NlQ3KM7:TR?=	NH;Ib25USU6JRWK=
CAPAN-1	NFjOTXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LTUWlEPTB;Nz6yOFM2QSEQvF2=	M1;obHNCVkeHUh?=
NCI-H82	NVf0PGlbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTdwMk[2OVkh\|ryP	MYDTRW5ITVJ?
G-402	NWSxO5pST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV2xR\|RRUUN3ME23MlMxODVzIN88US=>	M1jUTXNCVkeHUh?=
SW982	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\TTWM2OD15LkOwNlA{KM7:TR?=	NFLqW2hUSU6JRWK=
OVCAR-4	NHHWR4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTdwM{GzNlgh\|ryP	NIrXbZBUSU6JRWK=
KARPAS-299	M1rKXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\2TWM2OD15LkOyOlIzKM7:TR?=	NWXvVJpKW0GQR1XS
MIA-PaCa-2	M1;yNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmDXTWM2OD15LkO2PFI{KM7:TR?=	NXfN[4U{W0GQR1XS
AU565	M4DqRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLlTWM2OD15LkW5PFM{KM7:TR?=	NF3seGJUSU6JRWK=
GAMG	NF;wOYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF[4UJNKSzVyPUeuOlQyOzFizszN	NVTRb2t5W0GQR1XS
HuO9	NYS4PGhXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PKZWlEPTB;Nz63NVc1OyEQvF2=	M37MWnNCVkeHUh?=
ACN	NWnGTpBKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPqWpVKSzVyPUeuO\|Q{OyEQvF2=	NH3JXWZUSU6JRWK=
RO82-W-1	NWj3PHZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{GyUWlEPTB;Nz63OFU{OyEQvF2=	NWC3UFZ[W0GQR1XS
NKM-1	NFv5RWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXqTWM2OD15Lke0PVU2KM7:TR?=	MXXTRW5ITVJ?
CAL-12T	NWfSbZBET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHW5OZNKSzVyPUeuPVQ{PTJizszN	Mn;mV2FPT0WU
FADU	NELYV5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPZN4FxUUN3ME24MlA{PjV2IN88US=>	NWHYNWVxW0GQR1XS
NCI-H28	NX;D[nRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2jNfGlEPTB;OD6xOlk3OiEQvF2=	MknjV2FPT0WU
LCLC-97TM1	NGO3flVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHJTWM2OD16LkKxNVIzKM7:TR?=	MWrTRW5ITVJ?
CHP-134	NV\FVllUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLITWM2OD16LkK0NVg2KM7:TR?=	MmrsV2FPT0WU
HT-1080	NISzbYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRThwMkWwPVMh\|ryP	Ml25V2FPT0WU
PC-3	NXHSPZVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjjR4hWUUN3ME24MlI4Ozl{IN88US=>	MnjyV2FPT0WU
SNU-449	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;2OWlEPTB;OD6yO\|k{KM7:TR?=	NUjLR4RTW0GQR1XS
VA-ES-BJ	NWrre4dYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\IfZNlUUN3ME24MlM1Pjh4IN88US=>	MoDNV2FPT0WU
HT	Mme5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\YfYNKSzVyPUiuN\|Y1QSEQvF2=	NFXiflNUSU6JRWK=
HOS	NUXiUZhVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfOcZdrUUN3ME24MlM4PTh7IN88US=>	M4HIOHNCVkeHUh?=
KNS-62	MkLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDoWIJKSzVyPUiuN\|c4PjJizszN	NFnmSXZUSU6JRWK=
OAW-42	MmHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRThwOUW5OlQh\|ryP	NIrRclhUSU6JRWK=
A549	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHqVZFKSzVyPUmuNFk3OTJizszN	MUXTRW5ITVJ?
CAKI-1	MmnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnIUotKUUN3ME25MlE3PjFizszN	MWnTRW5ITVJ?
HCC1937	M{nOemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoCxTWM2OD17Lk[5PFY2KM7:TR?=	MXvTRW5ITVJ?
GI-ME-N	NEW4RWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLJTWM2OD17LkewNVM4KM7:TR?=	NGjxTHBUSU6JRWK=
DU-4475	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;sU2lEPTB;OT65Olk{QSEQvF2=	M1K2W3NCVkeHUh?=
EM-2	NWPPeIJLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPzZWgzUUN3ME2xNE4zPDJ4IN88US=>	NVnNdHdoW0GQR1XS
NCI-H1755	NEPRSYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEHjV2tKSzVyPUGwMlI1OjhizszN	NIfPdXlUSU6JRWK=
NCI-H1437	M1[3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HjZmlEPTB;MUCuOVczPSEQvF2=	NV3JNZM3W0GQR1XS
VM-CUB-1	M4Dj[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTFyLk[xOlQh\|ryP	M{f0TnNCVkeHUh?=
A2058	NWn5OYpYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\6Nm5mUUN3ME2xNE43PDB2IN88US=>	MlnQV2FPT0WU
BPH-1	NUHacpJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTFyLkexOFUh\|ryP	MofZV2FPT0WU
NB5	MoP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\5RoNKSzVyPUGwMlc2PTlizszN	NHX6bGZUSU6JRWK=
G-401	Mki5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWf1N3duUUN3ME2xNE44PjJ4IN88US=>	MWPTRW5ITVJ?
CAL-72	M{DP[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4TmUmlEPTB;MUCuPFA6PCEQvF2=	NHT4ZmlUSU6JRWK=
SK-MEL-28	NY\vfocyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTFyLkiyNFIh\|ryP	NH61bo1USU6JRWK=
C32	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjFPJBKSzVyPUGwMlg{PDdizszN	NH;qdnlUSU6JRWK=
NCI-H1155	M3XjUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1mwPGlEPTB;MUCuPFM4PiEQvF2=	MlvlV2FPT0WU
BB49-HNC	NYD4PW1kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTFyLki1PFYh\|ryP	MlrvV2FPT0WU
GMS-10	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTFyLki5O\|Eh\|ryP	MofSV2FPT0WU
K5	MmL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLmTWM2OD1zMD65NFcyKM7:TR?=	MVzTRW5ITVJ?
OS-RC-2	NEX1WZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWrPb\|dCUUN3ME2xNU4xPTV7IN88US=>	NF3O[mhUSU6JRWK=
HTC-C3	M4G4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoS1TWM2OD1zMT6wO\|E1KM7:TR?=	MVLTRW5ITVJ?
LB996-RCC	M3fiNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;BUodxUUN3ME2xNU4xPzJ\|IN88US=>	NHzZV4FUSU6JRWK=
NCI-H1563	NV65TYZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHJTWM2OD1zMT6xNFEyKM7:TR?=	M3Tw[HNCVkeHUh?=
CAL-54	M{LNNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFX5b2tKSzVyPUGxMlQ5OTFizszN	NVr0bHVEW0GQR1XS
WM-115	NX;IXZpNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTFzLk[4NlQh\|ryP	M13hXHNCVkeHUh?=
COLO-684	MnroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXWc4NWUUN3ME2xNU44OjZ5IN88US=>	M{LmPXNCVkeHUh?=
HOP-62	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnkbpl5UUN3ME2xNU44PTB6IN88US=>	MXXTRW5ITVJ?
NCI-H650	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{j2Z2lEPTB;MUGuPFk3OSEQvF2=	MVXTRW5ITVJ?
TE-11	NX2wd4g4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfqSHJCUUN3ME2xNU46OzF3IN88US=>	M3\pR3NCVkeHUh?=
COLO-679	NV;nZ2RLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEflZ\|JKSzVyPUGxMlk1PiEQvF2=	MlPWV2FPT0WU
FTC-133	M17hPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYfsbJh3UUN3ME2xNk4xODd4IN88US=>	M4[yeXNCVkeHUh?=
D-283MED	NXvhU3V6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3oNo1KSzVyPUGyMlA2PjlizszN	Mm\LV2FPT0WU
SK-PN-DW	NHvzNWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3jaVmlEPTB;MUKuNVkxOiEQvF2=	MUjTRW5ITVJ?
BALL-1	NIHydGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHjrNXpKSzVyPUGyMlI3PjJizszN	MWjTRW5ITVJ?
GT3TKB	NUe0dXNRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTRTWM2OD1zMj6zNFc1KM7:TR?=	NUjKNo1IW0GQR1XS
HOP-92	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTF{LkWyN\|Mh\|ryP	NVviVYRZW0GQR1XS
M14	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjGTWM2OD1zMz6wN\|M2KM7:TR?=	NWWwR\|d1W0GQR1XS
SKG-IIIa	M4fhV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXGeHlKSzVyPUGzMlA2PTRizszN	NYTlbHdUW0GQR1XS
Becker	NFm2R45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\KVJpDUUN3ME2xN{4xPThizszN	NEj2bGpUSU6JRWK=
ES5	NGXY[GpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkC3TWM2OD1zMz6xN\|U3KM7:TR?=	M4iyVXNCVkeHUh?=
NCI-H2030	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDldms3UUN3ME2xN{4zODZ{IN88US=>	MVTTRW5ITVJ?
SNU-423	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rqO2lEPTB;MUOuN\|gyKM7:TR?=	MYrTRW5ITVJ?
CP50-MEL-B	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnYcnZKSzVyPUGzMlYzOzJizszN	MkToV2FPT0WU
NCI-H1092	MlPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmO1TWM2OD1zMz63OFc2KM7:TR?=	MU\TRW5ITVJ?
8-MG-BA	NV;LV4cxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDhTWM2OD1zMz63OVE{KM7:TR?=	NW\PfI1qW0GQR1XS
CAL-27	M4X1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnvDTWM2OD1zND6wO\|I4KM7:TR?=	NF7oRVhUSU6JRWK=
AGS	MmXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PDXWlEPTB;MUSuNVMyQSEQvF2=	MkHWV2FPT0WU
MZ2-MEL	M{HadWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{fqVmlEPTB;MUSuNVQ5QCEQvF2=	MkL6V2FPT0WU
BFTC-909	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{Xzc2lEPTB;MUSuOVA2PSEQvF2=	M2i3c3NCVkeHUh?=
D-566MG	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELzT3JKSzVyPUG0Mlc4ODZizszN	MlrIV2FPT0WU
MZ7-mel	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3Tsd2lEPTB;MUWuNVA3PyEQvF2=	MmjSV2FPT0WU
TE-5	MoHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXGTWM2OD1zNT6yN\|M{KM7:TR?=	M17XS3NCVkeHUh?=
647-V	M2LQWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTF3LkK3NFUh\|ryP	M1Xwc3NCVkeHUh?=
DMS-114	Mn23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTF3LkOyPVEh\|ryP	MX;TRW5ITVJ?
ME-180	NXqxfWc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjlWJVTUUN3ME2xOU41Pzh\|IN88US=>	MkPkV2FPT0WU
MS-1	NWjmTodOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUjJR\|UxRTF3LkW2NlMh\|ryP	NGjmfWxUSU6JRWK=
NUGC-3	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWPGdJpiUUN3ME2xOU43OjR3IN88US=>	MYLTRW5ITVJ?
GB-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTF3Lk[0N\|ch\|ryP	MX7TRW5ITVJ?
LOXIMVI	NFTyT\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXT[4p2UUN3ME2xOU45QTF7IN88US=>	MmXMV2FPT0WU
NCI-H1304	Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUX4bWV5UUN3ME2xOU45QTJ6IN88US=>	NXfhS4NQW0GQR1XS
KURAMOCHI	NUXicFVwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI[yToJKSzVyPUG1Mlk4OSEQvF2=	NIKzdW1USU6JRWK=
SW1783	NFrIcnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTF4LkC5PVMh\|ryP	M4G3c3NCVkeHUh?=
EGI-1	NUW4O2pCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDQVo45UUN3ME2xOk42OzZ3IN88US=>	NXLZZpZUW0GQR1XS
KGN	NIPETYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPDNmN1UUN3ME2xOk42PTh4IN88US=>	M4jSWXNCVkeHUh?=
PANC-03-27	M1vObWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTZTWM2OD1zNj63OlYzKM7:TR?=	NGHIepNUSU6JRWK=
RH-1	M4nxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfMPY9KSzVyPUG2MlgzPSEQvF2=	MmL5V2FPT0WU
HT-1376	NYna[mtrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LBb2lEPTB;MU[uPFQ1PiEQvF2=	MU\TRW5ITVJ?
ZR-75-30	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTF4LkmzOlEh\|ryP	NYHETpdyW0GQR1XS
TI-73	M1j2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGi5SWxKSzVyPUG2Mlk1ODhizszN	NVzpZmpbW0GQR1XS
TK10	M2PZWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfX[Hd1UUN3ME2xO{4xODd7IN88US=>	MmjxV2FPT0WU
SW684	MnjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTF5LkCxOVQh\|ryP	MWTTRW5ITVJ?
RPMI-8866	NXHEU3d{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTF5LkC2PVkh\|ryP	MlPUV2FPT0WU
LNCaP-Clone-FGC	M2S1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHUPIxmUUN3ME2xO{42OjBzIN88US=>	NYLwbnh2W0GQR1XS
NCI-H2291	M1G0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTF6LkSzOFUh\|ryP	NGTyTlVUSU6JRWK=
T47D	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3PN[GlEPTB;MUiuOFg5KM7:TR?=	NH;u[pFUSU6JRWK=
A204	M{fxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTF6LkW0OVIh\|ryP	MXvTRW5ITVJ?
HT-144	M2TRfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV[w[ZJsUUN3ME2xPE44PDJ5IN88US=>	NEPMPXFUSU6JRWK=
MDA-MB-361	MlPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTF7LkC3NVQh\|ryP	Ml;ZV2FPT0WU
HCC1806	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2C2bWlEPTB;MUmuNVU6OSEQvF2=	NEnEclVUSU6JRWK=
NCI-H596	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmLLTWM2OD1zOT62N\|kyKM7:TR?=	MWLTRW5ITVJ?
K-562	MlrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlPFTWM2OD1zOT64PVI3KM7:TR?=	NVq0fXl5W0GQR1XS
D-336MG	NWn1dXl[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfxZZdYUUN3ME2xPU46OzJ{IN88US=>	M3jDPXNCVkeHUh?=
SK-MEL-2	NFTweWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYS2PY9KUUN3ME2yNE4yPTV7IN88US=>	NVTKbHlZW0GQR1XS
HEC-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHEfHpKSzVyPUKwMlQ6PzhizszN	MVHTRW5ITVJ?
EW-13	NFvxXpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHm3T2FKSzVyPUKwMlU1PDNizszN	MmTxV2FPT0WU
Hs-578-T	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NETNR2NKSzVyPUKwMlU2QDNizszN	M2DiV3NCVkeHUh?=
SJSA-1	MlHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDaU\|NKSzVyPUKwMlU3QDhizszN	NYLFVppQW0GQR1XS
RCC10RGB	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnq4TWM2OD1{MD62O\|E6KM7:TR?=	MWfTRW5ITVJ?
LAN-6	M3HjWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHPb4NWUUN3ME2yNU4xOzl4IN88US=>	MnXTV2FPT0WU
NCI-H1048	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjxUm9QUUN3ME2yNU4zOjV6IN88US=>	M1jBTHNCVkeHUh?=
CW-2	NF3wcVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HoNWlEPTB;MkGuNlcxPSEQvF2=	MWrTRW5ITVJ?
HCC2157	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnXiTWM2OD1{MT6zOkDPxE1?	NHrUXFNUSU6JRWK=
EW-22	M1zNcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnQWpRWUUN3ME2yNU4{PzZizszN	NVLy[opyW0GQR1XS
A253	M1;0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4X3fGlEPTB;MkGuOFQ5OSEQvF2=	MWLTRW5ITVJ?
BE-13	M2PEWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIrSWHVKSzVyPUKxMlYyOTNizszN	NHHrZWJUSU6JRWK=
KINGS-1	NHP2cWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrzRZhqUUN3ME2yNU43OzF4IN88US=>	MWTTRW5ITVJ?
ETK-1	MmL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnwTWM2OD1{MT64NVUzKM7:TR?=	NIXjVYVUSU6JRWK=
NCI-H2452	NXryPVZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWD0SotlUUN3ME2yNU45PjR5IN88US=>	MmntV2FPT0WU
HPAF-II	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoKxTWM2OD1{MT64PVI{KM7:TR?=	NEHmcZNUSU6JRWK=
D-542MG	MlHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTJzLkmwOlkh\|ryP	NWXWUWJ1W0GQR1XS
NCI-H630	MkXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWDXfJJGUUN3ME2yNk4xOjl4IN88US=>	M{XE[HNCVkeHUh?=
TGBC11TKB	MnHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrIWGJKSzVyPUKyMlA1QSEQvF2=	NVTWVpJ5W0GQR1XS
BCPAP	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljYTWM2OD1{Mj62NVEh\|ryP	NX20W2ZVW0GQR1XS
HLE	MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnuTWM2OD1{Mj62PVch\|ryP	NXriPGdxW0GQR1XS
NCI-H727	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1WxPWlEPTB;MkKuO\|M2KM7:TR?=	MnvnV2FPT0WU
RD	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlrzTWM2OD1{Mj63OVE5KM7:TR?=	NWXWOW9yW0GQR1XS
NCI-H522	NYH1fIhpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPDTWM2OD1{Mj64OFMyKM7:TR?=	MYrTRW5ITVJ?
CGTH-W-1	NHL5VnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4G3[mlEPTB;MkOuNFY1OSEQvF2=	NEDKVm5USU6JRWK=
SK-LU-1	M2PFbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzBTWM2OD1{Mz60Olg{KM7:TR?=	M3\p[HNCVkeHUh?=
BB65-RCC	MmX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH23ZYVKSzVyPUKzMlc5PjNizszN	NGLydpNUSU6JRWK=
HSC-3	NIfvfnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHz2XoFKSzVyPUKzMlg2OjdizszN	MnXVV2FPT0WU
SK-MES-1	Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTJ2LkCxOlEh\|ryP	NEHjRZpUSU6JRWK=
DB	M1LydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULvXFJLUUN3ME2yOE4yODJ6IN88US=>	NVLOfmU3W0GQR1XS
HO-1-N-1	MkflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LybmlEPTB;MkSuN\|A6OyEQvF2=	Mn;wV2FPT0WU
MKN1	NYS5dYNGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWPIN2ZsUUN3ME2yOE43QCEQvF2=	MmHLV2FPT0WU
MN-60	MnfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkW4TWM2OD1{ND64OVE6KM7:TR?=	Mn\BV2FPT0WU
8505C	MlO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NISwNmVKSzVyPUK1MlE5PDVizszN	NHXSVFdUSU6JRWK=
COLO-320-HSR	NUixR2NvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmrVTWM2OD1{NT6yNlA5KM7:TR?=	M1LPeHNCVkeHUh?=
BB30-HNC	M1XS[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfRfoZKSzVyPUK1MlI1QDNizszN	Ml\DV2FPT0WU
KM12	NUHRTpJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;XeGlEPTB;MkWuOVgxPyEQvF2=	M{\oRnNCVkeHUh?=
NB13	NHKyS2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGLx[pNKSzVyPUK1MlU5QThizszN	NWm5ZXdQW0GQR1XS
HCC2998	Mn:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7yTWM2OD1{Nj6wNlg{KM7:TR?=	NEjHOW9USU6JRWK=
U-118-MG	NVj0RXBwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\ITm9KSzVyPUK2MlA5ODhizszN	NH;mOG5USU6JRWK=
NB10	MkfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXvJR\|UxRTJ4LkKzOEDPxE1?	MkHsV2FPT0WU
SK-LMS-1	M4PF[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vD[GlEPTB;MkeuNFcxPCEQvF2=	NIPjb5hUSU6JRWK=
SW1573	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NULw[ZE{UUN3ME2yO{4yOSEQvF2=	NHrwNZpUSU6JRWK=
LB373-MEL-D	NFHYeYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrQ[INFUUN3ME2yO{4yOjl2IN88US=>	M{jkRXNCVkeHUh?=
DK-MG	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;UTWM2OD1{Nz6xPFE4KM7:TR?=	MVjTRW5ITVJ?
RMG-I	MmDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTJ5LkKwNlkh\|ryP	M2jIO3NCVkeHUh?=
SW1088	NHrFR2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1TvSWlEPTB;MkeuOVA1OiEQvF2=	NYfqcXQyW0GQR1XS
SK-OV-3	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nWV2lEPTB;MkeuO\|U6OyEQvF2=	NIm2OmVUSU6JRWK=
KP-N-YN	NVP6RYFtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrnTWM2OD1{Nz64NFQ{KM7:TR?=	NXu2Tlg2W0GQR1XS
RPMI-7951	M13pOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTJ6LkK0OVYh\|ryP	NIHmfIpUSU6JRWK=
CaR-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfJdpdKSzVyPUK4MlU2QDJizszN	M3PUXXNCVkeHUh?=
MKN7	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTJ6LkW5OlQh\|ryP	M3vpSnNCVkeHUh?=
CHP-212	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHmwZWlKSzVyPUK4Mlc1ODFizszN	NY\nSmptW0GQR1XS
KYSE-450	MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mly3TWM2OD1{OD64NFkyKM7:TR?=	NFLrXFdUSU6JRWK=
RXF393	NFfIfIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{LTT2lEPTB;MkmuNlkxPiEQvF2=	Ml2yV2FPT0WU
P30-OHK	NWLTXpJmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkntTWM2OD1{OT6zNFQ5KM7:TR?=	Mnf4V2FPT0WU
Ca9-22	M17XXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHrDNpRKSzVyPUK5MlQzQTlizszN	MnHYV2FPT0WU
RT-112	NI\mTJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfGTWM2OD1{OT60OlEyKM7:TR?=	M2rkUXNCVkeHUh?=
ES1	NFnhUVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4TXSGlEPTB;MkmuPFU1PCEQvF2=	M4\wV3NCVkeHUh?=
HCE-4	NYHz[G93T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTJ7Lki3PFYh\|ryP	MmnaV2FPT0WU
AM-38	NGf2RW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlzQTWM2OD1\|MD6wOlA3KM7:TR?=	NVnIcYJTW0GQR1XS
AsPC-1	M{\CNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\OTWM2OD1\|MD64NFU{KM7:TR?=	NGLLWY9USU6JRWK=
TE-9	M17PO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTNyLki3N\|ch\|ryP	MoTqV2FPT0WU
HuP-T4	NXXsfml1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTNyLkm2N\|gh\|ryP	Ml3PV2FPT0WU
LB2518-MEL	NHPFUZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\lNVdmUUN3ME2zNU4xPzR2IN88US=>	MVrTRW5ITVJ?
NCI-H1703	NIrCSIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHvQb4VKSzVyPUOxMlA6ODVizszN	Mlv4V2FPT0WU
NCI-H2228	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXNTWM2OD1\|MT60OlUyKM7:TR?=	Mki1V2FPT0WU
SCC-4	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLmTWM2OD1\|MT65NVgyKM7:TR?=	MWDTRW5ITVJ?
KNS-81-FD	NXPWVoFqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTN{LkCxNlgh\|ryP	MX\TRW5ITVJ?
NTERA-S-cl-D1	NWXtWJdqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn[4TWM2OD1\|Mj6wO\|M6KM7:TR?=	M1PCXnNCVkeHUh?=
Daoy	NHzlToxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnHS4hKSzVyPUOyMlA5OzhizszN	Mlu1V2FPT0WU
ES4	NU\BVVRJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M13DbWlEPTB;M{KuN\|kzOiEQvF2=	MVTTRW5ITVJ?
MHH-ES-1	NGiyNpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jV[WlEPTB;M{KuOFg4OiEQvF2=	MkDPV2FPT0WU
C-33-A	NH\xe4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkT0TWM2OD1\|Mj63O\|I5KM7:TR?=	NFPSNohUSU6JRWK=
BHY	NETweoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTN{Lkm0PVUh\|ryP	NWm2WGpWW0GQR1XS
Detroit562	M2naRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7MTWM2OD1\|Mz62OlU4KM7:TR?=	MoO1V2FPT0WU
EW-1	NUS2ZXFTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17KR2lEPTB;M{OuPVMzOiEQvF2=	MkTpV2FPT0WU
NCI-H1395	Mn\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzNTWM2OD1\|ND6wO\|k6KM7:TR?=	NIjvc4FUSU6JRWK=
KM-H2	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTN4LkS3OFMh\|ryP	MVvTRW5ITVJ?
NCI-H520	NH:1ZldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTN4Lke1OFEh\|ryP	NWX5VlZqW0GQR1XS
D-392MG	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1ew[2lEPTB;M{euN\|M1PCEQvF2=	NY\JZ4dHW0GQR1XS
NOMO-1	M322XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;JTWM2OD1\|Nz64NFg6KM7:TR?=	M4XLZXNCVkeHUh?=
TE-6	M1HId2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDYTWM2OD1\|OD6xNlQh\|ryP	M3u4OnNCVkeHUh?=
HT-3	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTN6LkS0N\|Yh\|ryP	M1XBenNCVkeHUh?=
RPMI-8226	NVS4e45VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnyTWM2OD1\|OD65OVE6KM7:TR?=	M1Gze3NCVkeHUh?=
U251	NHn4d3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnrUTWM2OD1\|OT6wNVI1KM7:TR?=	M4PVSXNCVkeHUh?=
GCT	NHzvS4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3NfYZKSzVyPUO5MlE5PTJizszN	M4XrUXNCVkeHUh?=
A431	NXXIVoZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1TTemlEPTB;M{muNVg6PCEQvF2=	M37Gb3NCVkeHUh?=
TE-12	MmS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzrTWM2OD1\|OT6yOFQ5KM7:TR?=	M3P3OXNCVkeHUh?=
HMV-II	M3jTSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33rNGlEPTB;M{muOVA1PyEQvF2=	NVThVGdZW0GQR1XS
IST-MES1	NWqwWVRbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTRyLkG1NFIh\|ryP	M2rWbHNCVkeHUh?=
SW13	MnPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXHN4dKSzVyPUSwMlUyQSEQvF2=	NHfifWFUSU6JRWK=
SF295	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFXxXG5KSzVyPUSwMlgxPjZizszN	NHfndldUSU6JRWK=
MDA-MB-157	NF\DZpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjSOIl5UUN3ME20NE46PDZ{IN88US=>	M1u1XHNCVkeHUh?=
TE-1	NETPNJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2jTOmlEPTB;NEGuPFcyPCEQvF2=	NEHvW2tUSU6JRWK=
HuCCT1	M1\OPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3FNJFKSzVyPUSyMlUzQDlizszN	MVnTRW5ITVJ?
KYSE-510	NFnXXIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTR\|LkG3OVQh\|ryP	MkTMV2FPT0WU
NCI-H358	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmn0TWM2OD12ND6wN\|A1KM7:TR?=	NGjqToVUSU6JRWK=
SW900	M1;WXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjGTWM2OD12ND6wO\|U5KM7:TR?=	MkOyV2FPT0WU
CAS-1	NHHGcXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPCTWM2OD12ND6wPVkyKM7:TR?=	NHniTHRUSU6JRWK=
TE-8	NF;oVG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;UUmNKSzVyPUS0MlU3PThizszN	NGTBW5BUSU6JRWK=
P12-ICHIKAWA	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\Qb2lEPTB;NESuOlEyOiEQvF2=	Mn7hV2FPT0WU
YKG-1	NFO3bYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTBbHdKSzVyPUS0Mlc5OSEQvF2=	NGrJNnJUSU6JRWK=
SNU-C2B	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV\JR\|UxRTR2Lke5NFMh\|ryP	MkLLV2FPT0WU
LCLC-103H	M1nTPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXldXZKSzVyPUS0Mlg4ODNizszN	MkPsV2FPT0WU
U-87-MG	NYD4[FVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTR3LkGwNlIh\|ryP	NYrDRoVnW0GQR1XS
HAL-01	MlTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LFNGlEPTB;NEWuNVM4QSEQvF2=	MX;TRW5ITVJ?
OVCAR-8	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;ubGlEPTB;NEWuN\|U3PCEQvF2=	MXTTRW5ITVJ?
KYSE-150	NIjJd4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XofGlEPTB;NEeuNVA2OiEQvF2=	Ml25V2FPT0WU
OE33	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnXcpJzUUN3ME20O{4yPDJ7IN88US=>	MXTTRW5ITVJ?
CAL-62	NEHyOGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTR5LkSwOlgh\|ryP	MlvxV2FPT0WU
TCCSUP	MmjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTR5Lk[yOlQh\|ryP	MWnTRW5ITVJ?
H4	M4HKVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrpTWM2OD12Nz62OlIyKM7:TR?=	NIO5fXhUSU6JRWK=
CP66-MEL	NW\pWI5RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF6wbXpKSzVyPUS4MlA4ODRizszN	M3XjUXNCVkeHUh?=
SNB75	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NITmSYJKSzVyPUS4MlE5PzRizszN	Ml7mV2FPT0WU
Mo-T	MnnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnpTWM2OD12OD6yO\|kh\|ryP	MUTTRW5ITVJ?
BT-549	NXzLRYZQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTR6LkO3Nlkh\|ryP	M4jZW3NCVkeHUh?=
IGR-1	NWjzZVRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV:4T4VoUUN3ME20PE43PjR3IN88US=>	MoL5V2FPT0WU
NCI-H1299	M1X6cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTR6LkeyOFgh\|ryP	NELNcG5USU6JRWK=
ALL-PO	M2jSPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M37Ie2lEPTB;NEmuPVI3QCEQvF2=	MXnTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-DNA-PKcs / DNA-PKcs / p-ATM / ATM / p-ATR / ATR / Ku70 / p-CHK1 / p-CHK2/ p-AKT / RAD51; PubMed: 29344644 Oncol Rep SUNE1 cells were irradiated with 5 Gy in the presence or absence of NU7441 (2 µM). The expression of cell cycle checkpoint proteins and double strand break repair proteins was assayed by western blot analysis at 6 or 12 h post-IR. p-mTOR(Ser2448) / mTOR / p-S6K(Thr389); PubMed: 25714019 Oncotarget Phosphorylation of mTOR and p70S6K were detected by Western blot analysis 24 hours after treatment.	29344644 25714019

In vivo

NU7441 intraperitoneally administrated at dose of 10 mg/kg maintains for at least 4 hours shows nontoxic and increases etoposide-induced tumor growth delay 2-fold in mice bearing SW620 xenografts. ^[2]

Protocol

Cell Research:

^[2]

- Collapse

Cell lines: SW620, LoVo, V3-YAC and V3 cells
Concentrations: 0.5 μM or 1 μM
Incubation Time: 17 hours
Method:
The effect of NU7441 on cellular survival following exposure to etoposide, doxorubicin, and ionizing radiation is measured in SW620, LoVo, V3, and V3-YAC cells by clonogenic assays. Briefly, growing cells in six-well plates or 6-cm dishes are exposed to etoposide or doxorubicin with or without NU7441 (0.5 or 1.0 μM) for 16 hours. For radiosensitization studies, NU7441 is added to the cells 1 hour before irradiation. V3 and V3-YAC cells are exposed to γ-irradiation (3.1 Gy/min ¹³⁷Cesium). SW620 and LoVo are exposed to X-irradiation (2.9 Gy/min at 230 kV, 10 mA) due to the equipment available. After irradiation, the cells are incubated with or without NU7441 for a further 16 hours. Cells are then harvested by trypsinization, counted, and seeded into 10-cm diameter Petri dishes at densities varying from 100 to 10⁵ per dish in drug-free medium for colony formation. Colonies are stained with crystal violet after 10 to 14 days and counted with an automated colony counter. The survival reduction factor (SRF) is calculated as the surviving fraction of cells in the absence of NU7441 divided by the surviving fraction of cells in the presence of NU7441 for any given dose or concentration of cytotoxic agent. The dose modification ratio (DMR90) is calculated as the concentration/dose of cytotoxic agent required to kill 90% of the cells in the absence of NU7441 divided by the concentration/dose of cytotoxic agent required to kill 90% of the cells in the presence of NU7441.

(Only for Reference)

Animal Research:

^[2]

- Collapse

Animal Models: Female rude mice bearing SW620 xenografts
Dosages: 10 mg/kg
Administration: Intraperitoneally administrated
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	4 mg/mL warmed (9.67 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download NU7441 (KU-57788) SDF

Molecular Weight	413.49
Formula	C₂₅H₁₉NO₃S
CAS No.	503468-95-9
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC5=C4SC6=CC=CC=C56

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Could you please suggest formulations of the drug for in vivo injection?
Answer:
We tested the following formulation for in vivo use, 4% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 1mg/mL. It is a clear solution.
Question 2:
Previous aliquots were clear and colorless while this time, it becomes yellow when the powder was dissolved in DMSO? Could you advice on this?
Answer:
Slight color variation due to different processing is normal and usually doesn't interfere with the function.

DNA-PK Signaling Pathway Map

DNA-PK Inhibitors with Unique Features

Non-specific DNA-PK Inhibitor

PI-103 : DNA-PK, IC50=23 nM; p110α/β/δ/γ, IC50=2 nM/3 nM/3 nM/15 nM; mTOR, IC50=30 nM.
Most Potent DNA-PK Inhibitor

PIK-75 : DNA-PK, IC50=2 nM.
Newest DNA-PK Inhibitor

KU-0060648 : Dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM.
Classic DNA-PK Inhibitor

NU7026 : Potent DNA-PK inhibitor with IC50 of 0.23 μM, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR.

Related DNA-PK Products

CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs. CHIR99021 functions as a Wnt/β-catenin activator and induces autophagy.
Dorsomorphin (Compound C) ^New

Dorsomorphin (Compound C, BML-275) is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Dorsomorphin selectively inhibits the BMP type I receptors ALK2, ALK3 and ALK6. Dorsomorphin is used in promoting specific cell differentiation and inducing cancer cell line autophagy.
MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
NU7026

NU7026 (LY293646) is a potent DNA-PK inhibitor with IC50 of 0.23 μM in cell-free assays, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR. NU7026 enhances G2/M cell arrest and apoptosis.
KU-0060648

KU-0060648 is a dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus, AY 22989, NSC-2260804) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. MK-2206 2HCl induces autophagy and apoptosis in cancer cells. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.
CHIR-99021 (CT99021) HCl

CHIR-99021 (CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2. CHIR-99021 is a potent pharmacological activators of the Wnt/beta-catenin signaling pathway. CHIR-99021 significantly rescues light-induced autophagy and augments GR, RORα and autophagy-related proteins.
LY294002

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.

Choose Your Country or Region

By Signaling Pathways

By product type

NU7441 (KU-57788)